-
Nov 27, 2024 | 00519-3?rss=yes&sz=64)
cell.com | Lucy Macdonald |Aziza Elmesmari |Domenico Somma |Jack Frew |Clara Di Mario |Roopa Madhu | +30 more
Keywordsimmune tolerancearthritisdisease remissiondendritic cellssynovial tissuespatial transcriptomicsT cellsIntroductionRheumatoid arthritis (RA) is an inflammatory joint disease with systemic comorbidities, driven by the breach of immune tolerance.1 Advances in targeted therapies2 have transformed the management of RA.
-
Jul 31, 2024 | 
acrjournals.onlinelibrary.wiley.com | Iain B McInnes |Philip Mease |Yoshiya Tanaka |Kitakyushu Japan
INTRODUCTION Psoriatic arthritis (PsA) is a progressive, long-term, chronic inflammatory disease characterized by symptoms affecting a variety of tissues.
-
Nov 10, 2023 | 
ard.bmj.com | Roy Fleischmann |Vibeke Strand |Tatsuya Atsumi |Iain B McInnes
AbstractObjectives To investigate the efficacy and safety of otilimab, an antigranulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis. Methods Two phase 3, double-blind randomised controlled trials including patients with inadequate responses to methotrexate (contRAst 1) or conventional synthetic/biologic disease-modifying antirheumatic drugs (cs/bDMARDs; contRAst 2).
-
Nov 10, 2023 | 
ard.bmj.com | Peter Taylor |Michael E Weinblatt |Iain B McInnes |Tatsuya Atsumi
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3) Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Nov 3, 2023 | 
nature.com | Georg Schett |Iain B McInnes
AbstractDepression is a common and disabling comorbidity in rheumatoid arthritis that not only decreases the likelihood of remission and treatment adherence but also increases the risk of disability and mortality in patients with rheumatoid arthritis. Compelling data that link immune mechanisms to major depressive disorder indicate possible common mechanisms that drive the pathology of the two conditions.
-
Oct 27, 2023 | 
nature.com | Jinrong Fu |Guoping Lu |Iain B McInnes |Chuan Qin |Yufeng Zhou
AbstractCytokine storms are crucial in the development of various inflammatory diseases, including sepsis and autoimmune disorders. The immunosuppressive cytokine INTERLEUKIN (IL)-37 consists of five isoforms (IL-37a-e). We identified IL-37a as a nuclear cytokine for the first time. Compared to IL-37b, IL-37a demonstrated greater efficacy in protecting against Toll-like receptor-induced cytokine hypersecretion and lethal endotoxic shock.
-
Oct 12, 2023 | 
ard.bmj.com | Christopher T. Ritchlin |Laura Coates |Iain B McInnes |Philip Mease
Up to Week 52, 555/702 (79.1%; EAIR/100 PY: 222.5) patients reported ≥1 TEAE while receiving BKZ treatment, including patients who switched from PBO to BKZ at Week 16; 113/140 (80.7%; EAIR/100 PY: 209.4) ADA-treated patients reported ≥1 TEAE to Week 52. Up to Week 52, 46 (6.6%; EAIR/100 PY: 7.9) patients receiving BKZ treatment and 10 (7.1%; EAIR/100 PY: 7.5) patients receiving ADA treatment reported an SAE.
-
Sep 12, 2023 | 
ard.bmj.com | Roy Fleischmann |Vibeke Strand |Tatsuya Atsumi |Iain B McInnes
In contRAst 1, otilimab 90 mg resulted in a significantly greater proportion of patients achieving CDAI LDA at week 12 vs placebo, but otilimab 150 mg did not (20.9% (p=0.0188) and 19.8% (p=0.0368) vs 13.9%). In contRAst 2, both doses resulted in a significant difference versus placebo (26.5% and 25.1%, respectively, vs 11.4%, p<0.0001 for both) (figure 2, table 2, online supplemental figure 3).
-
Sep 11, 2023 | 
ard.bmj.com | Peter Taylor |Michael E Weinblatt |Iain B McInnes |Tatsuya Atsumi
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3) Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Sep 11, 2023 | 
ard.bmj.com | Christopher T. Ritchlin |Laura Coates |Iain B McInnes |Philip Mease
DiscussionBE OPTIMAL demonstrated long-term efficacy of BKZ up to Week 52 in patients with active PsA who were bDMARD-naïve across a range of PsA domains, including joints, skin, enthesitis, dactylitis and nails, as well as the inhibition of structural progression. Improvements in efficacy as assessed by stringent outcome measures were sustained from Week 16 to Week 52 with BKZ treatment, with a low rate of patient drop-out. Furthermore, safety was as expected with no new safety signals observed.
